GDC and SCH single treatments each partly reduced levels of the ERK target phospho-S265-FRA1 and these levels were further reduced in tumors treated with GDC + SCH, verifying the on-target activity of SCH and demonstrating a stronger inhibition of RAS signaling by the dual therapy. Here, MAPK1 is linked to spindle cell hemangioma.